Britain and America have finalized a landmark commercial pact that will preserve zero levies on British medicine products entering the American market.
Agreement Details of the Pact
As part of the deal, the UK has agreed to increase spending on pharmaceuticals through the NHS. This pledge secures that import taxes on these key products will remain at zero for a duration of the next three years.
This deal comes after previous threats to dramatically increase tariffs on branded drug products, with figures discussed up to 100%.
"This agreement with the Britain bolsters the global environment for cutting-edge drugs and brings much-needed fairness to American-British pharmaceutical trade," a release declared.
Trade Importance
Drugs represent one of the the United Kingdom's biggest export categories to the United States, which is by far the largest destination for leading UK drugmakers.
Export figures indicate that in the 12 months to the end of last September, the UK shipped medicines worth billions to the US. This figure accounted for a significant portion of all goods exports in that period.
"This deal safeguards work, stimulates investment and sets the stage for the UK to emerge as a international leader for medical research," a minister commented.
Key British Pledges
The pact involves several notable changes from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it deems new therapies to be too expensive by 25%.
- Higher Drug Budget: There is a goal to increase total health service expenditure on treatments from 0.3% of GDP to 0.6 percent over the coming ten years.
- Refund Ceiling: The amount manufacturers must refund to the NHS to control costs will be limited at fifteen percent. Previously, rebates exceeded 20%.
Industry Background
The deal comes amid a long-running dispute between the drug companies and the UK government over spending levels and NHS adoption.
This friction were heightened by claims that US consumers were paying several times more for the same drugs than patients in the UK and Europe.
Over the last 18 months, several significant pharmaceutical investments in the UK have been delayed or cancelled, while substantial funding commitments have been pledged toward American operations.
One official publicly accepted that the NHS needed to invest a greater share on drugs, noting that its spending on drugs had decreased as a proportion of its total funding over the past decade.
